Close Menu

NEW YORK – Atyr Pharma on Thursday said it would work with the Medical University of South Carolina (MUSC) to develop antibodies for lung cancer that target neuropilin-2 (NRP2).

Robert Gemmill, a hematology and oncology professor at MUSC, whose research focuses on the role of genetic alterations involved in lung and kidney cancers, including NRP2, will serve as principal investigator of the research program.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Dec
02
Sponsored by
Qiagen

The Phosphoinositide 3-Kinase (PI3K) pathway is one of the most frequently altered pathways in human cancer and plays a significant role in disease progression and resistance to endocrine therapy.